Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX) and ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...

Moderna Inc.’s stock tumbled 4% Thursday after a report that health officials are reviewing a contract the company won from the Biden administration to support efforts to develop a bird-flu ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in the waning days of the Biden administration. “While it is crucial that ...

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with five new international lawsuits. It’s the latest development in a bitter ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...

In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna ...

based Moderna by the Biomedical Advanced Research and Development Authority, a division of HHS. The contract, signed in the final days of the Biden administration, is designed to help Moderna ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...